Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP. Lin NU, et al. Among authors: christodoulou c. Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080. Clin Cancer Res. 2009. PMID: 19228746 Clinical Trial.
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G. Christodoulou C, et al. J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7. J Neurooncol. 2017. PMID: 28687923 Clinical Trial.
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V, Tsakiri K, Koliou GA, Lazaridis G, Papadopoulou K, Giannoulatou E, Tikas I, Christodoulou C, Chatzopoulos K, Bobos M, Pentheroudakis G, Tsolaki E, Batistatou A, Kotsakis A, Koutras A, Linardou H, Razis E, Res E, Pectasides D, Fountzilas G. Kotoula V, et al. Among authors: christodoulou c. Clin Breast Cancer. 2019 Apr;19(2):113-125.e4. doi: 10.1016/j.clbc.2018.10.014. Epub 2018 Nov 5. Clin Breast Cancer. 2019. PMID: 30545790
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G. Razis E, et al. Among authors: christodoulou c. Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Clin Breast Cancer. 2012. PMID: 22607768
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Fountzilas G, et al. Among authors: christodoulou c. Clin Breast Cancer. 2003 Jun;4(2):120-5. doi: 10.3816/cbc.2003.n.017. Clin Breast Cancer. 2003. PMID: 12864940
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. Fountzilas G, et al. Among authors: christodoulou c. Cancer Invest. 2004;22(5):655-62. doi: 10.1081/cnv-200032980. Cancer Invest. 2004. PMID: 15581045 Clinical Trial.
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P. Fountzilas G, et al. Among authors: christodoulou c. Cancer Invest. 2008 Oct;26(8):784-93. doi: 10.1080/07357900801918611. Cancer Invest. 2008. PMID: 18798073 Clinical Trial.
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Rigakos G, Razis E, Koliou GA, Oikonomopoulos G, Tsolaki E, Sperinde J, Chrisafi S, Zarkavelis G, Pazarli E, Batistatou A, Kourea HP, Papakostas P, Bafaloukos D, Asimakopoulou NI, Res E, Kotsakis A, Pectasides D, Koutras A, Christodoulou C, Fountzilas G. Rigakos G, et al. Among authors: christodoulou c. Anticancer Res. 2021 Apr;41(4):1793-1802. doi: 10.21873/anticanres.14945. Anticancer Res. 2021. PMID: 33813384
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G. Gogas H, et al. Among authors: christodoulou c. Breast Cancer Res Treat. 2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4. Epub 2011 Dec 21. Breast Cancer Res Treat. 2012. PMID: 22187126 Clinical Trial.
508 results